Cardiology

Kass explains recent findings from a study that suggest myocardial dysfunction in HFpEF may be reversible with weight loss.

Kass explains 2 distinct biological subgroups discovered in HFpEF and how they relate to a paradigm shift.

Propensity-matched data link empagliflozin to lower risk of CV events, AKI, and other outcomes versus dapagliflozin in type 2 diabetes.

Shoamanesh discusses the positive data from OCEANIC-STROKE, a phase 3 trial comparing the investigative FXIa inhibitor to placebo in patients with prior ischemic stroke.

Patel provides an inside perspective on one of the most diagnostically challenging cardiovascular conditions.

Blood discusses his recent study of the RECTIFIER AI model, highlighting its superior sensitivity and accuracy compared to physicians.

Mokashi discusses 2 recent studies which he co-authored, investigating the socioeconomic impacts on health across America and the healthcare sector’s growth.

Schneider discusses her analysis of the FINEARTS-HF trial, noting the apparent efficacy of finerenone regardless of sleep apnea presence.

Stay updated with the latest healthcare breakthroughs, including FDA actions, in this week’s essential news roundup.

Christensen discusses the mechanics and practical applications of the HFMS, emphasizing its success in predicting HF events based on pulmonary fluid levels.

Nissen discusses his post-hoc analysis of the SURPASS-CVOT trial, comparing the 2 drugs for a 6-component composite endpoint of cardiorenal outcomes.

Troy discusses the recent changes to the ABCs of CVD, highlighting an increased focus on lifestyle interventions and the management of risk factors.

Catapano discusses the superior reduction in LDL-C, ApoB, and non-HDL-C demonstrated by enlicitide, suggesting its role as an add-on for LDL-C lowering.

Vaidya discusses the 2022 pulmonary arterial hypertension guidelines and how they can be made more accessible for clinicians just entering the field.

Catch up on major trial results, groundbreaking guideline updates, and more.

March 2026 cardiology updates feature key ACC.26 data, new guidelines, and advances in PAH, AF, hypertension, and lipid management.

Singh discusses his analysis of all 3 parts of the NODE-301 phase 3 trial, investigating the recently approved CBB’s potential risk of hypotension.

O’Donoghue addresses the inherent limitations in the ACS guidelines, from the constant influx of further research to the ambiguity of certain treatment recommendations.

Navar discusses the phase 3 CORALreef AddOn trial, highlighting enlicitide’s superiority to ezetimibe, bempedoic acid, and a combination of both.

Butt discusses his secondary analysis of the FINEARTS-HF trial, which demonstrated consistent treatment efficacy in patients with and without a history of IHD.

Catch up on data from some of the most impactful trials presented at the American College of Cardiology 2026.

Gomberg-Maitland addresses sotatercept’s capacity to improve pulmonary vascular and cardiac endpoints in patients with CpcPH-HFpEF.

Catch up on the most impactful trial readouts to come out of ACC 2026.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.